Tweets
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.
#EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv.
https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @drminidey
OP0165- incidence & risk factors of D2T RA in an early RA cohort
Factors assoc with D2T RA:
🩸 Seropositivity
🦴 Erosions
📈 Disease activity
📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approved 2 other biosimilars to ustekinumab, including ustekinumab-aekn (Selarsdi) and ustekinumab-auub (Wezlana). https://t.co/BgYQm39aEB https://t.co/XZhnHxPaP0
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
How do you manage new progressive ILD?
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @drdavidliew
"We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something to be very proud of. Let’s not forget that!
5y mortality from DANBIO
(still, we still have work to do in seropos RA in men!)
#EULAR2024 OP0162
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @drdavidliew
"I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.
https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
No Risk of Interstitial Lung Disease with Methotrexate Use
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
https://t.co/qauRelAkG0 https://t.co/bhSLYrfzlv
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
